DOCSLIB.ORG

Pharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011. The tutorial was developed by composite authors of the Department of Pharmacology, Clinical Pharmacology and Pharmacoeconomics of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖. © V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov 2 3 V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT Student___________________________________________________ Course_________Group_________________Decade______________ Faculty___________________________________________________ Teacher _________________________________________________ Academic year________ / __________ 3 4 № Module 1 Maximal grade topics General prescription. General pharmacology. Drugs affecting the synapses. Drugs affecting the peripheral and central nervous system Semantic unit № 1 General prescription 1. Ukrainian law «About medical drugs». Introduction into general prescription. 6 The solid dosage forms. 2. The soft dosage forms. 6 3. Liquid dosage forms. Solutions for intrernal and external use and for 6 injection, aerosoles. 4. Potions, decoctions, and solutions that dosed in drops and spoons. 6 5. The final lesson on general prescription. 6 Semantic unit № 2 History of Pharmacology and Pharmacy Common pharmacology 6. Introduction into pharmacology. Pharmacology and pharmacy development. 6 The final lesson on common pharmacology. Semantic unit № 3 Agents acting on the peripheral afferent and efferent nervous system 7. Local anesthetics, astringent, absorbent, irritating drugs. Mucos membrane 6 protectors. 8. M, N cholinomimetics, anticholinesterase agents. М-cholinoblockers. 6 N-cholinoblockers (ganglioniс blockers, neuromuscular blocking drugs) 9. Agents affecting on adrenoreceptors. Adrenomimetics drugs, 6 sympathomimetics. 10. Antiadrenergic drugs: adrenoblockers and, sympatholytics. 6 11. Dopaminergic, serotoninergic drugs. 6 The final lesson on agents acting on the peripheral afferent and efferent nervous system. Semantic unit №4 Drugs acting on the central nervouse system 12. Psychotropic drugs. Sedative drugs, neuroleptics, tranquilizers (Anxiolytics 6 drugs), mood stabilizers. 13. Hypnotics drugs, antiepileptic and antiparkinsonic drugs. 6 14. General anaesthetics. Pharmacology and toxicology of ethyl alcohol. 6 15. Narcotic (Opioid) analgesics 6 16. Non-narcotic (non-opioid) analgesics. Nonsteroidal anti-inflammatory drugs 6 17. Psychomotor stimulants. Analeptics. Antidepressants. Nootropic drugs. 6 Adaptogenes. Actoprotectors. 18. The final lesson on drugs acting on the central nervouse system. 6 4 5 № Module 2 Maxim al topics Pharmacology of medications that affect on function of the executive body’s grade systems, metabolism, blood and immune system. Pharmacology of antimicrobial, antiviral, antiparasitic and antifungal medications Semantic unit №5 Pharmacology of metabolism 1. Theme 16. Pharmacology of the endocrine system. Hormonal agents, their synthetic 6 substitutes and antagonists. 2. Theme 17. Pharmacology of vitamins. Enzyme preparations and their inhibitors. 6 3. Theme 18. Pharmacology of a blood system. Pharmacology of substances affecting 6 hematopoiesis. Medications affecting blood coagulation, platelet aggregation, and fibrinolysis. 4. Theme 19. Allergy and immunotropic medications. 6 The final lesson «Pharmacology of metabolism». Semantic unit №6 Pharmacology of Medications which affect the function of organs and physiological systems 5. Theme 20. Pharmacology of the respiratory system. 6 6. Theme 21. Pharmacology of the digestive system 6 7. Theme 22. Pharmacology circulation. Hypo-and hypertensive agents. 6 Antihyperlipidemic agents. Angioprotectors. 8. Theme 23. Pharmacology of the coronary and cerebral blood flow. Antianginal and 6 cerebrovascular medications 9. Theme 24. Cardiotonic medications.Antiarrhythmic medications 6 10. Theme 25. Pharmacology of agents affecting water and electrolyte balance. 6 Arthrifuge. 11. Theme 26. Uterine medications and contraceptives. 6 Test control «Pharmacology of medications which affect the function of organs and physiological systems». 12. The final lesson «Pharmacology of medications which affect the function of 6 organs and physiological systems». Semantic unit 7 Pharmacology of antimicrobial, antiviral, antiparasitic, antifungal Medications 13. Theme 27. Antiseptics and disinfectants. Sulfonamides. Fluoroquinolones. 6 14. Theme 28. Antibiotics I (β - lactams, macrolides, aminoglycosides). 6 15. Theme 29. Antibiotics II (tetracyclines, chloramphenicol). Anti-fungal, anti- 6 viral, antitubercular medications. 16. Theme 30. Antiparasitic, anti-cancer medications. 6 The final lesson «Pharmacology of antimicrobial, antiviral, antiparasitic, antifungal medications». 17. Drugs affecting the mucous membranes of the mouth and tooth tissue. 18. Pharmacology of acute poisoning. Pharmacovigilance for side effects of medications.The final test control Module-2. 19. The final control Module-2. «Pharmacology of medications which 80 affect the function of the executive bodies, metabolism, blood system and immune system.Pharmacology of antimicrobial, antiviral, antiparasitic and antifungal Medications» Together semantic units 112 Student individual self-study (ISS) 8 Total 200 5 6 Note: After getting the traditional marks the student receives the following points. Practical classes: «5» – 6 «4» – 4 «3» – 3 «2» – 0 Final classes: «5» – 6 «4» – 4 «3» – 3 «2» – 0 Requirements for admittance to the final module control: routine academic performance with a minimal sum of grades 51 points in every semester passing the final test control with a result more than 75% 6 7 PLAN OF LECTURES (First semester) №№ LECTURE’S TOPICS History of the pharmocology development. Modern pharmacology 1. condition. Ukrainian law «About medical drugs». General pharmacology. Agents acting on the peripheral efferent nervous system. M, N cholinomimetics, anticholinesterase agents. М-cholinoblockers. N-cholinoblockers (ganglioniс blockers, neuromuscular blocking drugs) 2. Agents affecting on adrenoreceptors. Adrenomimetics drugs, sympathomimetics. Antiadrenergic drugs: adrenoblockers and, sympatholytics. Psychotropic drugs. Sedative drugs, neuroleptics, tranquilizers (Anxiolytics 3. drugs), mood stabilizers, salts of lithium. Hypnotics drugs, antiepileptic and antiparkinsonic drugs. Clinical use. Pharmacology of paid and anesthetics. General anesthetcs. 4. Classification of analgesics. Narcotic analgesics. Non-narcotic (non- opioid) analgesics. Nonsteroidal anti-inflammatory drugs. Pharmacology of drugs affecting the respiratory and digestive 5. system. 7 8 PLAN OF LECTURES (Second semester) №№ LECTURE’S TOPICS Pharmacology of the respiratory system: decongestants, expectorant, antitussive and bronchodilators. 1 Pharmacology of the digestive system. Medications affecting motor and secretory activity of the stomach and intestines. Hepatotropic and pankreatotropnye medications. Pharmacology of systemic, coronary and cerebral circulation. Antihypertensive, antianginal and cerebro-vesselactive medications. 2 Pharmacology of heart failure. Cardiac medications of glycoside and aglycoside nature. Antiarrhythmic medications. Pharmacology of antimicrobial agents (AA). Antiseptics and disinfectants. Synthetic AA: sulfonamides, derivatives nitroimidazole quinoxaline. 3 General principles of rational antibiotic therapy. Pharmacology of β-lactam antibiotics. Aminoglycosides. Macrolides. Chloramphenicol and tetracycline.
Recommended publications
  • Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
  • Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals

    Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals

    section P m e ] Analytical кгейг“' Control i - ¡ Q f Radiopharmaceuticals Proceedings of a Panel Vienna, • ° 7-11 July 1969 INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1970 ANALYTICAL CONTROL OF RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GREECE .NORWAY ALBANIA GUATEMALA PAKISTAN ALGERIA HAITI PANAMA ARGENTINA HOLY SEE PÂRAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES BELGIUM INDIA POLAND BOLIVIA INDONESIA PORTUGAL BRAZIL IRAN ROMANIA BULGARIA IRAQ' SAUDI ARABIA BURMA IRELAND SENEGAL BYELORUSSIAN SOVIET ISRAEL SIERRA LEONE SOCIALIST REPUBLIC ITALY SINGAPORE CAMBODIA IVORY COAST SOUTH AFRICA CAMEROON JAMAICA SPAIN CANADA JAPAN SUDAN CEYLON JORDAN SWEDEN CHILE KENYA SWITZERLAND CHINA KOREA, REPUBLIC OF SYRIAN ARAB REPUBLIC COLOMBIA KUWAIT THAILAND CONGO, DEMOCRATIC LEBANON TUNISIA REPUBLIC OF LIBERIA TURKEY COSTA RICA LIBYAN ARAB REPUBliC UGANDA CUBA LIECHTENSTEIN UKRAINIAN'SOVIET SOCIALIST CYPRUS LUXEMBOURG REPUBLIC CZECHOSLOVAK SOCIALIST MADAGASCAR UNION OF SOVIET SOCIALIST REPUBLIC MALAYSIA REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGER VIET-NAM GERMANY, FEDERAL REPUBLIC OF NIGERIA YUGOSLAVIA GHANA *• ZAMBIA The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters,
  • The Anthelmintic Niclosamide Is a Potent TMEM16A Antagonist That Fully Bronchodilates Airways

    The Anthelmintic Niclosamide Is a Potent TMEM16A Antagonist That Fully Bronchodilates Airways

    bioRxiv preprint doi: https://doi.org/10.1101/254888; this version posted January 27, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The anthelmintic niclosamide is a potent TMEM16A antagonist that fully bronchodilates airways Kent Miner1, Benxian Liu1, Paul Wang2, Katja Labitzke2,†, Kevin Gaida1, Jian Jeffrey Chen3, Longbin Liu3,†, Anh Leith1,†, Robin Elliott1, Kathryn Henckels1, Esther Trueblood4,†, Kelly Hensley4, Xing-Zhong Xia1, Oliver Homann5, Brian Bennett1, Mike Fiorino1, John Whoriskey1, Sabine Escobar1, Gang Yu1, Joe McGivern2, Min Wong1, Teresa L. Born1,†, Alison Budelsky1,†, Mike Comeau1, Dirk Smith1,†, Jonathan Phillips1, James A. Johnston1, Kerstin Weikl2,†, David 2 1,* 2,†.* 1,† ,* Powers , Deanna Mohn , Andreas Hochheimer , John K. Sullivan 1Department of Inflammation Research, Amgen Inc., Thousand Oaks, CA and Seattle, WA, USA 2Department of Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, USA and Regensburg, Germany 3Department of Medicinal Chemistry, Amgen Inc., Thousand Oaks, CA, USA 4Department of Comparative Biology and Safety Sciences, Amgen Inc., Seattle, WA, Thousand Oaks, CA and South San Francisco, CA, USA 5Genome Analysis Unit, Amgen Inc., South San Francisco, CA, USA †Present address; see Additional Information section *Corresponding authors. E-mails: [email protected] (J.K.S); [email protected] (A.H.); [email protected] (D.M.) Abstract There is an unmet need in severe asthma where approximately 40% of patients exhibit poor -agonist responsiveness, suffer daily symptoms and show frequent exacerbations. 2+ Antagonists of the Ca -activated-Cl¯ channel, TMEM16A, offers a new mechanism to bronchodilate airways and block the multiple contractiles operating in severe disease.
  • Addictions and the Brain

    Addictions and the Brain

    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
  • Focus on Over-The-Counter Drugs' Misuse: a Systematic Review On

    Focus on Over-The-Counter Drugs' Misuse: a Systematic Review On

    SYSTEMATIC REVIEW published: 07 May 2021 doi: 10.3389/fpsyt.2021.657397 Focus on Over-the-Counter Drugs’ Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants Fabrizio Schifano 1, Stefania Chiappini 1,2*, Andrea Miuli 2, Alessio Mosca 2, Maria Chiara Santovito 2, John M. Corkery 1, Amira Guirguis 3, Mauro Pettorruso 2, Massimo Di Giannantonio 2 and Giovanni Martinotti 2 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Department of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University, Chieti, Italy, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea Edited by: University, Swansea, United Kingdom Nicolas Simon, Aix Marseille Université, France Background: Over the past 20 years or so, the drug misuse scenario has seen the Reviewed by: Nicolas Franchitto, emergence of both prescription-only and over-the-counter (OTC) medications being Université Toulouse III Paul reported as ingested for recreational purposes. OTC drugs such as antihistamines, Sabatier, France Oussama Kebir, cough/cold medications, and decongestants are reportedly the most popular in being Institut National de la Santé et de la diverted and misused. Recherche Médicale (INSERM), France Objective: While the current related knowledge is limited, the aim here was to *Correspondence: examine the published clinical data on OTC misuse, focusing on antihistamines Stefania Chiappini (e.g., diphenhydramine, promethazine, chlorpheniramine, and dimenhydrinate), [email protected] dextromethorphan (DXM)- and codeine-based cough medicines, and the nasal Specialty section: decongestant pseudoephedrine. This article was submitted to Methods: A systematic literature review was carried out with the help of Scopus, Addictive Disorders, a section of the journal Web of Science databases, and the related gray literature.
  • Anti-Inflammatory Effects of Amantadine and Memantine

    Anti-Inflammatory Effects of Amantadine and Memantine

    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes

    Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes

    molecules Article Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes Zeynep Mirza 1, Ernesto R. Soto 1 , Yan Hu 1,2, Thanh-Thanh Nguyen 1, David Koch 1, Raffi V. Aroian 1 and Gary R. Ostroff 1,* 1 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; [email protected] (Z.M.); [email protected] (E.R.S.); [email protected] (Y.H.); [email protected] (T.-T.N.); [email protected] (D.K.); raffi[email protected] (R.V.A.) 2 Department of Biology, Worcester State University, Worcester, MA 01602, USA * Correspondence: gary.ostroff@umassmed.edu; Tel.: 508-856-1930 Academic Editor: Vaclav Vetvicka Received: 2 June 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Soil-transmitted nematodes (STN) infect 1–2 billion of the poorest people worldwide. Only benzimidazoles are currently used in mass drug administration, with many instances of reduced activity. Terpenes are a class of compounds with anthelmintic activity. Thymol, a natural monoterpene phenol, was used to help eradicate hookworms in the U.S. South circa 1910. However, the use of terpenes as anthelmintics was discontinued because of adverse side effects associated with high doses and premature stomach absorption. Furthermore, the dose–response activity of specific terpenes against STNs has been understudied. Here we used hollow, porous yeast particles (YPs) to efficiently encapsulate (>95%) high levels of terpenes (52% w/w) and evaluated their anthelmintic activity on hookworms (Ancylostoma ceylanicum), a rodent parasite (Nippostrongylus brasiliensis), and whipworm (Trichuris muris). We identified YP–terpenes that were effective against all three parasites.
  • Lifestyle in Pregnancy

    Lifestyle in Pregnancy

    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/25835221 Lifestyle in Pregnancy Article in Canadian family physician Médecin de famille canadien · October 1984 Source: PubMed Central CITATIONS READS 4 26 2 authors: Robert Bryce Murray Enkin Flinders University McMaster University 44 PUBLICATIONS 650 CITATIONS 149 PUBLICATIONS 5,877 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Clinical skills education in the MD program View project All content following this page was uploaded by Murray Enkin on 18 May 2014. The user has requested enhancement of the downloaded file. Robert L. Bryce Murray W. Enkin Lifestyle in Pregnancy SUMMARY SOMMAIRE While there is little doubt about the Bien qu'il ne subsiste que peu de doute quant a la relation entre le mode de vie et son influence sur le association of lifestyle and pregnancy resultat de la grossesse, on questionne enormement outcome, there is considerable doubt about la valeur nette, pendant la grossesse, des the net value of lifestyle adjustments during changements au niveau du mode de vie. On n'a pas pregnancy. Advice alone on nutrition, sexual demontre qu'a eux seuls, les conseils sur la activity, alcohol and smoking in pregnancy nutrition, l'activite sexuelle, la consommation has not been demonstrated to improve d'alcool et le tabagisme pendant la grossesse ont ameliore la situation et qu'ils pr'sentent en soi des outcome, and may, in itself, have adverse effets adverses. Certains effets benefiques peuvent effects. Beneficial effects may occur when se manifester lorsque les conseils s'accompagnent advice is accompanied by a program of social d'un programme de support social.